All posts by imreal

New Research to Study Impact of a Service Dog Training Program for Children with Autism and their Families


HABRI Logo

More data demonstrating the benefits of service dogs for autistic individuals will empower families to make more informed decisions regarding how to support the health and wellbeing of their family.

The Human Animal Bond Research Institute (HABRI) announced funding for a new research project to evaluate the impact of a service dog training program and service dog matching on autistic children and their families. This grant was awarded to Gretchen Carlisle, Ph.D., at the Research Center for Human-Animal Interaction, University of Missouri College of Veterinary Medicine.

One in 44 children in the United States is estimated to be born with autism spectrum disorder. Autistic children may have differences in social interaction and communication, and may also struggle with comorbid conditions such as anxiety. Behavioral care and supportive interventions are key to aiding autistic children and their families. Scientific research demonstrates the benefits of dog ownership for autistic children and their families can include increased social skills and reduced family stress, yet there is a lack of research on the potential benefits of service dogs for this population.

“Service dogs represent a relatively new yet increasingly popular approach for assisting families that include an autistic child,” said the study’s Principal Investigator, Dr. Carlisle. “This research will further our understanding of the impact of these dogs on the health and wellbeing of autistic children and their families.”

Preliminary research conducted by Dr. Carlisle highlights the importance of families viewing their pet dogs as a good match with their children, for the families to experience benefits. Service dogs, with a high level of training and predictable calm temperament, are theorized to be more likely to be accepted as a good match by a family that includes an autistic child. This study will use a cross-sectional survey of parents of autistic children. Data collected will be used to compare those who are on a waitlist to receive a service dog, those who are in the training process to be matched with a service dog, and those who are already matched with a service dog. A longitudinal study will also be conducted following parents of autistic children as they progress from the waitlist through the training process and up to one year after matching with a service dog.

“We expect to find autistic children and their families will benefit from participating in a service dog training program and being matched with a service dog, including displaying reduced symptoms of autism, lower anxiety, and improved family function,” explained Dr. Carlisle. “It is our hope this research can be used to inform service dog training organizations and parents considering a service dog for their autistic child.”

“More data demonstrating the benefits of service dogs for autistic individuals will empower families to make more informed decisions regarding how to support the health and wellbeing of their family,” said Steven Feldman, President of HABRI. “HABRI is proud to fund this project from the University of Missouri, which we hope will provide new evidence supporting the human-animal bond as a source of comfort and support for autistic children.”

About HABRI

HABRI is a not-for-profit organization that maintains the world’s largest online library of human-animal bond research and information; funds innovative research projects to scientifically document the health benefits of companion animals; and informs the public about human-animal bond research and the beneficial role of companion animals in society. For more information, please visit http://www.habri.org.

Share article on social media or email:

Prevent Blindness Revamps, Expands its “Living Well With Low Vision” Online Resource


News Image

Prevent Blindness unveils newly re-designed, updated Living Well With Low Vision online resource.

“Today we are proud to offer our newly expanded resource to provide patients with the necessary information they need to live their most fulfilling lives,” said Jeff Todd, president and CEO of Prevent Blindness.

To provide comprehensive information and a user-friendly experience to the millions of low vision patients, their caregivers, and healthcare professionals, Prevent Blindness, the nation’s leading eye health and safety nonprofit organization, is launching the newly redesigned resource, “Living Well With Low Vision.”

Low Vision is defined as vision loss that cannot be corrected by medical or surgical treatments or conventional eyeglasses, according to the American Academy of Ophthalmology. Although low vision can occur at any age, it is primarily associated with older populations.

According to The Vision Council, one in 28 Americans ages 40 and above have low vision, often caused by age-related eye diseases including cataract, age-related macular degeneration, diabetes-related retinopathy, and glaucoma. Low vision disorders are often accompanied by other health dangers such as increased risk of falling, chronic disease, anxiety, and social isolation.

Updates to the new Living Well With Low Vision resource from Prevent Blindness include:


  •     A redesign with attention to accessibility incorporating tools to help people with low vision or other disabilities navigate the site easily, including improved accessibility for the “Self-Help Guide to Non-Visual Skills” and “The ABC’s of Caring for the Visually Impaired” handbook
  •     Updated interactive guides (GuideMe Patient Guides) for people who have been diagnosed with age-related macular degeneration and diabetes-related retinopathy
  •     A new section on vision loss and mental wellness
  •     Updated patient and caregiver resource directories (e.g. low vision aids, service directories)
  •     Updated links for resources for healthcare professionals, and to the latest research, disease-specific news, and clinical trials

Website content and accessibility are guided by the all-volunteer Living Well With Low Vision Advisory Committee, comprised of a diverse range of stakeholders, including individuals living with vision loss.

This resource is supported by grants from Genentech and Horizon Therapeutics.

To help users navigate the new site, Prevent Blindness is hosting a free webinar, “Introducing a New Low Vision Resource from Prevent Blindness,” to be held on Nov. 16, 2022, at 6 p.m. ET. The discussion will specifically address what low vision is and how to use the new Prevent Blindness website to address the many issues that can come with vision loss.

Speakers to include:

  •     R. Tracy Williams, OD, FAAO (Moderator); Executive Director, Spectrios Institute; Clinical Professor, Department of Ophthalmology; Loyola University
  •     Virginia A. Jacko, President & CEO of Miami Lighthouse for the Blind and Visually Impaired
  •     Ken West, Senior Director of Communications, Prevent Blindness
  •     Dan Roberts; Editor, Living Well With Low Vision; Patient Advocate with AMD

“When we first launched our Living Well With Low Vision resource almost 10 years ago, it was one of the first national programs to specifically address the needs of patients and their caregivers who were facing the many challenges of vision loss,” said Jeff Todd, president, and CEO of Prevent Blindness. “Today we are proud to offer our newly expanded resource to provide patients with the necessary information they need to live their most fulfilling lives.”

For more information on Living Well With Low Vision, or other general eye health information, please visit https://lowvision.preventblindness.org/ or https://preventblindness.org/.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs, and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at PreventBlindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn, and YouTube.                                                                 ###

Share article on social media or email:

QSM Diagnostics and Mella Pet Care Integrate Platforms for Infection Testing


Streamlining one platform benefits both startups and veterinary professionals. Now, we’ve created the ability to send infection test results directly back into the patient record, said Anya Babbitt, co-founder and CEO of Mella Pet Care.

Mella Pet Care, an ecosystem of health monitoring solutions for veterinarians and pet parents, announced its integration with QSM Diagnostics, a medical device company that develops instruments and test kits for bacterial identification, resulting in faster recovery with targeted treatment. This collaboration will allow users to employ a singular platform to ease the adoption of new technologies into veterinary clinics.

All users of the Mella Desktop Application – which allows Mella customers to enjoy seamless integration with any Patient Management System on Mac and Windows – will now be able to operate the QSM Otter eQ instrument out of the box on their pre-existing platform, removing the necessity to run separate software. The Mella Application will guide users through the testing process to prevent errors. QSM users will automatically receive test results and store reports in their Patient Management System.

Mella, whose Mella Pro Smart Underarm Thermometers are in approximately 1,000 veterinary clinics worldwide, and QSM Diagnostics, are unveiling the addition of the QSM OTTER eQ instrument platform into the Mella Desktop Application. This test is improving antibiotic stewardship for veterinarians by increasing the accuracy of identifying bacterial infections.

“Veterinarians are busy and frequently don’t have the time to learn new technology,” said Anya Babbitt, co-founder and CEO of Mella Pet Care. “Streamlining one platform benefits both startups and veterinary professionals. Now, we’ve created the ability to send infection test results directly back into the patient record.”

Veterinarians are excited to use Mella and the QSM OTTER eQ. Alex Schechter, DVM, Founder of Burrwood Veterinary in Birmingham Michigan, said, “In the current setting, veterinarians cannot identify the bacterial species present in a sample, leading to incorrectly prescribed antibiotics 20-25% of the time.”

“No pet parent wants to be part of the 20% that receive the wrong antibiotics. That’s one in five who have to come back because their pet keeps getting worse due to an incorrect medication,” said Ed Goluch, Founder and CEO of QSM Diagnostics. With QSM’s faster bacterial detection and identification, veterinarians can prescribe targeted antibiotics for their patients.

For more information about both companies and their offerings, visit mella.ai and qsmdiagnostics.com. Mella will be offering QSM products, as part of the strategic partnership, at http://www.mella.ai/qsm.

Review the Mella Press Kit for images, product shots, videos, and more. Join Mella and QSM on Tuesday, November 8th at 1pm CST for an exclusive webinar on the partnership.

About Mella Pet Care

Mella Pet Care, a Chicago-based startup, is building the future of pet care with an ecosystem of health monitoring solutions for veterinarians and pet parents, including the first-ever accurate axillary thermometer, a body fat analyzer, a chip reader, pulse ox, and more. Preventative tools are now accessible, allowing pets to live longer, happier lives. Mella has won 14 industry awards including the 2021 Purina Pet Care Innovation Prize and Mars’ 2022 Leap Venture Studio accelerator. Mella is accepting orders for both Mella Pro and Home Thermometers on their website.

About QSM Diagnostics

Boston, Massachusetts-based QSM Diagnostics is fundamentally changing how infections are diagnosed and treated. The company’s patented technology allows veterinarians to provide better treatment for their patients and helps mitigate the spread of antimicrobial resistance by making testing faster and easier. QSM’s products also increase pet owner engagement and improve drug administration compliance by educating and involving owners in their pet’s health. QSM diagnostics won multiple animal health industry awards, including the 2021 Animal Health Innovation Award and the 2022 Purina Pet Care Innovation Prize.

Share article on social media or email:

Shady Grove Fertility (SGF) continues to expand its care team throughout Maryland, Northern Virginia, and D.C. to better serve those in need of fertility care


SGF continues to expand its care team throughout Maryland, Northern Virginia, and D.C.

“SGF is unique in that its providers are committed to patient care, committed to conducting research that continues to explore ways to best treat individuals and couples struggling with infertility, and committed to developing future clinicians in this field.”

US Fertility, the largest physician-owned and physician-led, integrated network of top-tier fertility practices in the United States, expands access to fertility care by welcoming Alexandra Gannon, M.D.;Jerrine R. Morris, M.D., M.P.H., FACOG; Matthew T. Connell, D.O.; and Laura X. Zalles, M.D., to Maryland, Northern Virginia, and D.C., Shady Grove Fertility care teams.

“I’m continually inspired by my patients,” shares Dr. Gannon. “The mental fortitude, drive, and sacrifice it takes to walk this journey is humbling. I strive to do my best every day knowing what brought my patients here.”

To expand care in Northern Virginia and Maryland, Dr. Gannon will provide patient care at SGF’s Fair Oaks, Virginia, and Rockville, Maryland, locations and is now scheduling new patient appointments. Dr. Gannon is board certified in obstetrics and gynecology (OB/GYN) and board eligible in reproductive endocrinology and infertility (REI). Dr. Gannon has contributed to numerous publications and presentations, focusing on topics such as oncofertility, polycystic ovary syndrome (PCOS), and the effects of stress on fertility treatment. Dr. Gannon presented her most recent research at this year’s American Society for Reproductive Medicine (ASRM) annual meeting, “Obese PCOS Displayed Compromised Glucose Metabolism Along with Altered Feeding, Sleeping and Activity Patterns,” for which she was lead author. She is a member of several professional societies, including the American College of Obstetrics and Gynecologists (ACOG) and the (ASRM).

Those in Baltimore can have greater access to top-tier family building services as Dr. Morris will provide patient care at SGF’s Baltimore – Harbor East, Maryland, location and is now scheduling new patient appointments. Dr. Morris is board certified in OB/GYN and board eligible in REI. Dr. Morris has contributed to numerous publications and presentations, focusing on topics such as PCOS, third-party reproduction, and disparities in reproductive health access and treatment outcomes. Dr. Morris hosted a roundtable during the ASRM Congress and Expo this year, “Identifying and Reducing Unconscious Bias in the Workforce: Techniques to Improve Equitable Treatment of Women, and Racial, Ethnic, and Sexual Minority Physicians in Medicine,” a symposia titled, “Identifying and Breaking Down Barriers to Utilization of Male Fertility Care,” and a faculty, interactive session, “Building Diversity, Equity and Inclusion into a Reproductive Practice.” She is a member of several professional societies, including ACOG, ASRM, and the National Medical Association (NMA).

“SGF is unique in that its providers are committed to patient care, committed to conducting research that continues to explore ways to best treat individuals and couples struggling with infertility, and committed to developing future clinicians in this field,” adds Dr. Morris.

Starting later this fall, Dr. Connell will provide patient care at SGF’s Annapolis and Waldorf, Maryland, locations and is now scheduling new patient appointments. Dr. Connell is board certified in OB/GYN and REI. His clinical interests include all aspects of male and female infertility with specific focus on recurrent pregnancy loss, PCOS, premature ovarian insufficiency, diminished ovarian reserve, endometriosis, and fertility preservation. Dr. Connell joined SGF in 2020 and has previously seen patients in central Pennsylvania.

“SGF provides world-class care to their patients,” shares Dr. Connell. “By offering a collaborative approach to fertility care, I am honored to walk alongside my patients in their family-building journeys.”

Dr. Zalles has also joined the SGF team as a Research Associate and also provides monitoring for patients at the Rockville, Maryland, and K Street, Washington, D.C., locations. Dr. Zalles is board certified in OB/GYN and preparing for REI fellowship. Recognized for her excellence in research, Dr. Zalles has contributed to numerous publications and presentations exploring topics such as fertility preservation for cancer patients, donor eggs, genetic disorders, and fertility care for Black and Hispanic women. Her most recent research, “Differences in Reproductive and Neonatal Outcomes Based on Time Interval From Cesarean Section to Frozen Embryo Transfer” for which she was lead author, was presented at ASRM this year.

Serving patients from D.C. to Baltimore Harbor to Fair Oaks and in between, SGF offers patients access to the most advanced fertility treatments and unique financial options available. Patients can be sure that SGF offers innovative, compassionate fertility care through many renowned programs and accolades such as:


  • Over 100,000 babies born
  • Internationally renowned Donor Egg Program, among the largest in the nation. All donors are fully screened and ready to cycle.
  • Among the top 5 egg freezing programs in the U.S.
  • 100% refund guarantee options for IVF and donor egg
  • 96% of patients say they would refer a friend

Patients can schedule an appointment at any of the SGF locations throughout Maryland, Northern Virginia, and D.C. by calling the New Patient Center at 1-888-761-1967 or submitting this brief online form.

About US Fertility

US Fertility is the nation’s largest partnership of physician-owned and physician-led top-tier fertility practices, offering comprehensive fertility-market-focused non-clinical, administrative, and technical platforms that help domestic and international practices improve patient outcomes and increase patient access. To learn more about partnership- or affiliate-status benefits, call 301-545-1308 or visit USFertility.com.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 50 locations, including the newest location in Raleigh, North Carolina, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

How Site-Based eSource Benefits Sponsors by Boosting Site Success, Upcoming Webinar Hosted by Xtalks


It is a widely held, but false belief that sites currently use electronic health records (EHR) for source data collection, but they don’t.

eSource is the only data repository that documents protocol and GCP compliance, patient safety and directly integrates clinical care and research. Sponsors can promote better outcomes and help improve data precision by encouraging site-based eSource across their participating sites. It is a widely held, but false belief that sites currently use electronic health records (EHR) for source data collection, but they don’t.

Historically, sites have used error-prone paper, but over the last decade, maturation of the research site industry has driven a shift towards adoption of site-based eSource. With built-in quality up front, site eSource opens up radical new ways of reorganizing monitoring and data management workflows to improve efficiency and data quality.

Register for this webinar and join the featured speaker, to unravel the myths about site-based eSource, and understand the downstream efficiencies to sponsors and CROs.

Join Raymond Nomizu, CEO & Co-Founder, CRIO, for the live webinar on Friday, November 11, 2022, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit How Site-Based eSource Benefits Sponsors by Boosting Site Success.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Clinically-Relevant Biomarker Strategies in Drug Development and the Potential of Machine-Learning for Biomarker Assessment, Upcoming Webinar Hosted by Xtalks


The real value of biomarker insights have not been fully realized due the limitations in the development and implementation of effective biomarker strategies in many clinical programmes across therapeutic areas, resulting in the absence of predictive biomarkers in the latest drug approvals.

Biomarker quantification plays an integral role in the drug development process, providing guidance for downstream decision-making that has shown to correlate positively with clinical trial success. Biomarker-based stratification enriches clinical populations, reducing cost and trial duration. However, the real value of biomarker insights have not been fully realized due the limitations in the development and implementation of effective biomarker strategies in many clinical programmes across therapeutic areas, resulting in the absence of predictive biomarkers in the latest drug approvals.

It is also worth considering the prospect of applying machine-learning to biomarker assessment, which promises improved patient stratification of treatment response to drive drug development.

Register to learn about the importance of utilising biomarkers within clinical trials and how to go about developing effective biomarker strategies.

Join experts from Synexa Life Sciences, Justin Devine, CMO & Interim CSO; and Nicholas Woudberg, Scientific Engagement and Proposals Manager, for the live webinar on Friday, November 18, 2022, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Clinically-Relevant Biomarker Strategies in Drug Development and the Potential of Machine-Learning for Biomarker Assessment.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Automation of Solid-Phase Aromatic Foldamer Synthesis, Upcoming Webinar Hosted by Xtalks


The automation of the SPFS conditions is revolutionizing the production of high molecular weight aromatic oligoamides with very good yield and purity and faster production compared to the manual approach.

The synthesis of long helical oligoamide foldamers composed of more than 20 aromatic monomers of 8-amino-2-quinoline carboxylic acid can now be routinely achieved by using an in lab-developed solid-phase foldamer synthesis (SPFS) methodology that relies on acid chloride activation.

The automation of the SPFS conditions is revolutionizing the production of high molecular weight aromatic oligoamides with very good yield and purity and faster production compared to the manual approach. That constitutes a critical milestone in the field of aromatic foldamer chemistry with many concrete applications such as the modulation of protein-protein interactions in competitive research programs.

Register for this webinar to learn more on aromatic oligoamide foldamer (AOF) chemistry, automated parallel solid-phase foldamer synthesis on the PurePep® Chorus synthesizer — a next-generation, multi-scale peptide synthesis platform — and other applications.

Join Dr. Céline Douat, PhD, Scientific Co-Worker, Chair of Chemical Biology (Group of Prof. Ivan Huc), Dept. of Pharmacy, University of Munich (LMU), Germany, for the live webinar on Friday, November 18, 2022, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Automation of Solid-Phase Aromatic Foldamer Synthesis.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

FDA Clearance to Reprocess Da Vinci Robotic Instruments Could Present Hospitals with Substantial Savings


EndoWrist is a significant cost driver at U.S. hospitals, and we can now provide them with the option of reducing these costs significantly without having to abandon good instrumentation and the ability to perform robotic surgeries.

Iconocare, a healthcare cost containment company, today announced it has received FDA 510(k) clearance (#K210478) to reprocess and market used EndoWrist SI robotic attachments (8mm Monopolar Curved Scissors) originally produced by Intuitive Surgical, Inc., the company behind the Da Vinci robotic system.

Da Vinci robots are widely used in U.S. hospitals, and reusable accessories used in robotic procedures are very expensive and limited by the manufacturer to typically 10-15 uses. However, they can be used many more times when going through a controlled reprocessing process without losing functionality. Encore Medical Device Repair has exclusive distribution rights to FDA cleared reprocessed EndoWrist SI, and access to the EndoWrist XI is expected soon.

Reprocessed EndoWrist is significantly less expensive than new EndoWrist and can save the hospital hundreds of thousands of dollars. Using reprocessed EndoWrist poses no additional patient risk, and devices function as new.

“EndoWrist is a significant cost driver at U.S. hospitals, and we can now provide them with the option of reducing these costs significantly without having to abandon good instrumentation and the ability to perform robotic surgeries. This is the only FDA clearance for a robotic instrument, and we are very excited for the financial relief we can now provide to hospitals,” says Tom Milano, President & COO of Encore Medical Device Repair.

Iconocare is a healthcare cost containment company offering provider-focused healthcare solutions combining financial responsibility and healthcare technology to improve patient care.

Encore Medical Device Repair was founded in 2022 on the vision that device and instrument reuse should play a key role in responsible healthcare. To achieve this, the founders knew they had to raise the level of quality, sophistication, transparency, and service in the industry. A focus on the highest-price, highest-utilization instrument categories allows encore to employ the most qualified technicians and deliver unparalleled service while containing costs.

Share article on social media or email:

Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 37th Annual Meeting


News Image

“SITC is excited to incorporate these abstracts into an already impressive group of abstracts. The late-breaking abstracts will round out the content offered at the 37th Annual Meeting and highlight more cutting-edge research and data,” said SITC President Patrick Hwu, MD.

The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2022, more than 1,500, and has announced titles and authors for late-breaking abstracts (LBA). The abstracts will be presented at SITC’s upcoming 37th Annual Meeting & Pre-Conference Programs taking place November 8–12, 2022, in Boston, MA and virtually.

“SITC is excited to incorporate these abstracts into an already impressive group of abstracts. The late-breaking abstracts will round out the content offered at the 37th Annual Meeting and highlight more cutting-edge research and data,” said SITC President Patrick Hwu, MD.

The late-breaking abstracts are:

(1468) First data readout of standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration

Sarah Church, PhD – NanoString Technologies

(1469) A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease

Sandip Patel, MD – University of California San Diego Moores Cancer Center

(1470) Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)

Wade T. Iams, MD – Vanderbilt University Medical Center

(1471) Pharmacodynamic and predictive biomarkers associated with response in cancer patients treated with TPST-1120: a first-in-class, small molecule antagonist of Peroxisome-Proliferator Activated Receptor-Alpha

Nathan Standifer, PhD – Tempest Therapeutics

(1472) Assessing the Correlation between CD8 Cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 Cell Immunohistochemistry in Patients with Advanced Cancer Receiving Immunotherapy

Michael Postow, MD – Memorial Sloan Kettering Cancer Center

(1473) Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

Celeste Lebbe, MD, PhD – Université Paris Cite, Dermatolo-Oncology AP-HP Hôpital Sain

(1474) Cancer Vaccine Plus PD-1 Blockade Promotes Infiltration of Melanoma Metastases by Vaccine-Induced T Lymphocytes

Christine Tran, MD – University of Virginia

(1475) A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors

Paul Baverel, PhD – Molecular Partners AG

(1477) First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma.

Patrick Wen, MD – Dana Farber Cancer Institute

(1478) A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

Stefanie Mandl, PhD – PACT Pharma

Antoni Ribas, MD, PhD – University of California Los Angeles

The full abstracts will be available on Nov. 7 at 8 a.m. EST as a supplement published in the Journal for ImmunoTherapy of Cancer (JITC).

Late-Breaking Abstract Sessions with oral abstract presentations will take place on Thursday, Nov. 10 from 11:10–11:40 a.m. EST and Friday, Nov. 11 from 11:25–11:55 a.m. EST. Late-Breaking Abstract posters will be presented in the Poster Hall in Boston, MA and the virtual ePoster Hall beginning Thursday, Nov. 10 at 9 a.m. EST.

To learn more about the late-breaking abstracts, visit the 37th Annual Meeting & Pre-Conference Programs website.

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit http://www.sitcancer.org and follow us on Twitter, LinkedIn and YouTube.

Share article on social media or email:



Chaffin Luhana Foundation & Najee Harris Recognize Outstanding Student with 2022 Anti-Distracted Driving Scholarship


In an effort to drive down the staggering number of distracted driving accidents in the U.S., the Chaffin Luhana Foundation, Najee Harris, and his Da’ Bigger Picture Foundation have awarded their 2022 Anti-Distracted Driving Scholarship to one deserving student.

Both foundations are non-profit organizations that encourage the development of human potential and support community empowerment. This year, they have awarded a $2,500 scholarship to Morgan Zagorski, an undergraduate student at Indiana University of Pennsylvania, for her efforts to increase awareness of the dangers of distracted driving.

According to the most recent statistics from the National Highway Traffic Safety Administration (NHTSA), distracted driving claimed 3,142 lives in 2020. An estimated additional 324,652 people were injured in motor vehicle crashes involving distracted drivers.

Young adult and teen drivers remain the most at risk. A recent study from Autoinsurance.com revealed that more than 12 million teens are hitting the road, with 45 percent admitting to texting while driving. The AAA found in another study that driver distraction was responsible for more than 58 percent of teen crashes.

“Through my partnership with Chaffin Luhana, we are raising awareness of the dangers of distracted driving in the Pittsburgh area. Together, with our community, we have the power to help young people make the right decisions to keep themselves, and others safe,” says Harris.

For the essay contest, students had the option to write about a personal experience with distracted driving or to describe a realistic distracted driving awareness campaign that would reduce fatalities caused by distracted driving. As a third option, they could write about how technology and recent technological advancements have impacted the rise of distracted driving on our nation’s highways.

This year’s winner shared a personal experience with distracted driving. She explained in her essay that her uncle was walking home from dinner alone in 2012 when “a young girl hit him with her car as a result of distracted driving.”

The girl and her friend were racing down a busy road when they hit the writer’s uncle, throwing him 12 feet through the air. He was taken to the hospital, but he suffered from such extreme brain damage that he had to be put on life support. A few days later, his family had to make the difficult decision to withdraw that support. He passed away soon after, leaving behind a wife and three kids.

“I saw the impact of this destruction first hand,” Zagorski wrote, “and had to experience this loss with my family. Now that I am aware of the consequences of distracted driving, I make sure that I am a responsible driver so that no other family has to endure the pain of losing a loved one due to the mistakes of others.”

Chaffin Luhana has offered this scholarship for several years running, awarding one student each year with money to help them attend the college of their choice.

“Ms. Zagorsky’s essay reveals the tragic reality that many families face across our nation every day,” said Roopal Luhana, Partner at Chaffin Luhana. “Her willingness to share this experience and how it impacted her reveals a refreshing conscientiousness that we hope to encourage in other teen drivers across the country. Our hearts go out to her and her family.”

The firm has long believed in giving back to the community through charitable contributions, advancing scientific research, working to combat distracted driving, and providing scholarships to encourage students who are making a difference.

“Our aim is to raise awareness of distracted driving by giving students the opportunity to share their own experiences in a creative outlet,” said Eric Chaffin, Managing Partner of Chaffin Luhana. “And the response has been tremendous – each year we receive so many essays, most of which share first-hand experiences with distracted driving, along with lessons learned.”

About The Chaffin Luhana Foundation:

Law partners Eric Chaffin and Roopal Luhana, along with their families, established The Chaffin Luhana Foundation in 2010 to honor their humble roots and build upon the values of integrity and resilience instilled in them by their hardworking parents.

A not-for-profit organization, the Foundation encourages the development of human potential and supports community empowerment through the endowment of funds to deserving recipients, the creation of community-based enrichment projects, and the support of important scientific research that meaningfully impacts the underprivileged and sick in society.

With the goal of fostering acceptance, understanding, and an inclusive and healthy environment for everyone, the Foundation seeks to highlight individuals who are displaying outstanding characteristics in their lives, and bring all walks of life together in ways that invite positive interaction, while rewarding those resilient people willing to face difficult challenges, get back up, and surge forth once again. For more information, please visit ChaffinLuhanaFoundation.org.

About Da’ Bigger Picture Foundation:

Da’ Bigger Picture Foundation was founded by Najee Harris with the mission to help families experiencing homelessness and to assist low-income families achieve sustainable independence through a community-based response. Some of the key areas of focus are education, homelessness, addressing hunger and utilizing sports as a platform to develop life skills, as well as to advocate for public policies that alleviate poverty and promote the economic stability of low-income families. For more information, please visit Najee.net/pages/da-bigger-picture-foundation.

Share article on social media or email: